Glaucoma progression during the COVID-19 pandemics
DOI: 10.32364/2311-7729-2021-21-3-147-152
V.E. Korelina1, I.R. Gazizova2, A.V. Kuroyedov3,4, M.D. Didur2
1LLC “American Medical Clinic”, St. Petersburg, Russian Federation
2N.P. Bekhtereva Institute of the Human Brain, St. Petersburg, Russian Federation
3P.V. Mandryka Military Clinical Hospital, Moscow, Russian Federation
4Pirogov Russian National Research Medical University, Moscow, Russian Federation
The novel coronavirus infection (COVID-19) provides powerful effects on all pathogenic aspects of the primary open-angle glaucoma (POAG). The property of this virus to initiate disseminated intravascular coagulation, damage endotheliocytes, and impair coagulation result in numerous severe complications affecting all organs and systems. This disorder provokes retinal ischemia and hypoxia and spurs apoptosis of ganglionic cells. Cytokine storm and oxidative stress resulting from the COVID-19 potentially contribute to the progression of glaucomatous optic neuropathy. Distressing effect of the pandemic, a growing number of patients with depressive and anxiety disorders increase the risk of POAG and ocular hypertension, reduce treatment compliance, and exacerbate glaucoma course.
Ophthalmic patients should be informed on potential risks and consequences of the COVID-19 and educated on the safety and efficacy of vaccination and the need for these preventive measures for elderly patients (in particular, with glaucoma).
A year of the COVID-19 pandemic has radically changed the attitude to many processes of doctor-patient relationships. There is a need for the development of the technologies of distant monitoring of patients with glaucoma.
Keywords: primary open-angle glaucoma, COVID-19, telemedicine, pandemic, SARS-CoV-2, cytokine storm, oxidative stress, intraocular pressure, apoptosis of ganglionic cells, glaucomatous optic neuropathy, post-COVID-19 syndrome.
For citation: Korelina V.E., Gazizova I.R., Kuroyedov A.V., Didur M.D. Glaucoma progression during the COVID-19 pandemics. Russian Journal of Clinical Ophthalmology. 2021;21(3):147–152 (in Russ.). DOI: 10.32364/2311-7729-2021-21-3-147-152.
Acknowledgement
The Editorial Board is grateful to Sentiss for providing full-text foreign articles required to write the review.
About the authors:
1Viktoriya E. Korelina — C. Sc. (Med.), Head of Ophthalmological Department, lecturer of the Department of Family Medicine; ORCID iD 0000-0003-2022-5912.
2Il’mira R. Gazizova — Dr. Sc. (Med.), Head of the Department of Ophthalmology, academic secretary; ORCID iD 0000-0003-4611-9931.
3,4Aleksandr V. Kuroyedov — Dr. Sc. (Med.), Professor of the Department of Ophthalmology, Head of the Division of Ophthalmology; ORCID iD 0000-0001-9606-0566.
2Mikhail D. Didur — Dr. Sc. (Med.), Professor, Chief of Institute; ORCID iD 0000-0003-4086-5992.
1LLC “American Medical Clinic”. 78 letter A, river Moika embankment, St. Petersburg, 190000, Russian Federation.
2N.P. Bekhtereva Institute of the Human Brain. 9, Academician Pavlov str., St. Petersburg, 197376, Russian Federation.
3P.V. Mandryka Military Clinical Hospital, 8A, Bolshaya Olenya str., Moscow, 107014, Russian Federation.
4Pirogov Russian National Research Medical University. 1, Ostrovityanov str., Moscow, 117437, Russian Federation.
Contact information: Il’mira R. Gazizova, e-mail: ilmiraufa88@gmail.com.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 02.07.2021.
2. Loon S.-C., Teoh S.C.B., Oon L.L.E. et al. The severe acute respiratory syndrome coronavirus in tears. British Journal Ophthalmology. 2004;88(7):861–863. DOI: 10.1136/bjo.2003.035931.
3. Robbins S.G., Detrick B., Hooks J.J. Retinopathy following intravitreal injection of mice with MHV strain JHM. Adv Exp Med Biol. 1990;276:519–524.
4. Shindler K.S., Kenyon L.C., Dutt M. et al. Experimental optic neuritis induced by a demyelinating strain of mouse hepatitis virus. J Virol. 2008;82(17):8882–8886.
5. Hooks J.J., Percopo C., Wang Y. et al. Retina and retinal pigment epithelial cell autoantibodies are produced during murinecoronavirus retinopathy. J Immunol. 1993;151:3381–3389.
6. Yokota Sh., Kuroyva E., Nishioka K. New coronavirus disease (COVID-19) and “cytokine storm”. Prospects for effective treatment from the point of view of the pathophysiology of the inflammatory process. Infectious Diseases: News, Opinions, Education. 2020;9(4);13–25 (in Russ.). DOI: 10.33029/2305-3496-2020-9-4-13-25.
7. Sarzi-Puttini P., Giorgi V., Sirotti S. et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38(2):337–342.
8. Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. DOI: 10.1016/S2213-2600 (20) 30076-X.
9. Wu Y., Wu X., Chen Z. et al. Nervous system involvement after infection with COVID-19 and other viruses. Brain Behav Immun. 2020;87:1822. DOI: 10.1016/j.bbi.2020.03.031.
10. Rodriguez-Morales A.J., Cardona-Ospina J.A., Gutuerrez-Ocampo E. et al. Clinical, laboratory and imaging features of COVID-19: a systemic review and meta-analysis. Travel Med Infect Dis. 2020:101623. DOI: 10.1016/jrtmaid.2020.101623.
11. South A.M., Diz D., Chappel l. COVID-19, ACE2 and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5): H1084–1090. DOI: 10.1152/ajp-heart.00217.2020.
12. Erichev V.P., Petrov S. Yu., Subbot A.M. et al. The role of cytokines in the pathogenesis of eye diseases. National Journal of Glaucoma. 2017;16(1):87–101 (in Russ.).
13. Sawada H., Fukuchi T., Tanaka T., Abe H. Tumor necrosis factor-alpha concentrations in the aqueous humor of patients with glaucoma. Invest Ophthalmol Vis Sci. 2010;51(2):903–906. DOI: 10.1167/iovs.09-4247.
14. Tezel G., Li L.Y., Patil R.V., Wax M.B. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 2001;42(8):1787–1794.
15. Alexandrescu C., Dascalu A.M., Mitulescu C. et al. Evidence-based pathophysiology of glaucoma. Maedica. 2010;5(3):207–213.
16. Chernykh V.V., Shvayuk A.P., Gorbenko O.M. et al. Features of the pathogenesis of the initial and advanced stages of primary open-angle glaucoma. Allergology and Immunology. 2006;7(1):28–31 (in Russ.).
17. Chernykh V.V., Trunov A.N. Cytokines and growth factors in the pathogenesis of primary open-angle glaucoma. Ophthalmosurgery. 2020;(3):80–84 (in Russ.). DOI: 10.25276/0235-4160-2020-3-80-84.
18. Rukina D.A., Dogadova L.P., Markelova E.V. et al. Immunological aspects of the pathogenesis of primary open-angle glaucoma. RMJ Clinical Ophthalmology. 2011;4:162–165 (in Russ.).
19. Sokolov V.A., Levanova O.N., Nikiforov A.A. Matrix metalloproteinases-2 and -9 in the lacrimal fluid in patients with primary open-angle glaucoma. National Journal of Glaucoma. 2013;2(4):21–29 (in Russ.).
20. Erichev V.P., Egorov E.A. Pathogenesis of primary open-angle glaucoma. Bulletin of Ophthalmology. 2014;130(6):98–105 (in Russ.).
21. Flammer J., Haefliger I., Orqul S. Vascular dysregulation: a principal risk factor for glaucomatous damage? J Glaucoma. 1999;8:212–219.
22. Tezel G., Wax M.B. Hypoxia-inducible factor l-alpha in the glaucomatous retina and optic nerve head. Arch Ophthalmol. 2004;22:1348–1356.
23. Alekseev V.N., Gazizova I.R. Neurodegenerative changes in patients with primary open-angle glaucoma. Practical medicine. 2012;4:154–156 (in Russ.).
24. Alekseev V.N., Gazizova I.R., Nikitin D.N. Primary open-angle glaucoma and degenerative changes in the central parts of the visual analyzer. Ophthalmol statements. 2012;3:23–28 (in Russ.).
25. Kurysheva N.I., Irtegova E.Yu., Yasamanova A.N., Kiseleva T.N. Endothelial dysfunction and platelet hemostasis in primary open-angle glaucoma. National Journal of Glaucoma. 2015;14(1):27–36 (in Russ.).
26. Loskutov I.A. The role of microcirculation disorders in the vessels of the eye in the pathogenesis of glaucomatous neuropathy. Dis. doctor honey sciences. 2002 (in Russ.).
27. Shpak A.A., Gavrilova N.I., Lanevskaya N.I., Degtyareva M.V. Brain neurotrophic factor in patients with primary glaucoma. Ophthalmosurgery. 2006;4:14–16 (in Russ.).
28. Kurysheva N.I., Gavrilova N.A., Anikina A.Yu. Study of the neurotrophic factor BDNF in patients with primary glaucoma. Glaucoma. 2006;4:9–15 (in Russ.).
29. Korelina V.E., Chekurova L.V., Lauta V.F. Possibilities of neuroprotection in glaucoma. Glaucoma: theory and practice. Horizons of neuroprotection. 2014;9:43–47 (in Russ.).
30. Fomin N.E., Kuroedov A.V. Markers of vascular autoregulation in primary open-angle glaucoma. Clinical ophthalmology. 2019;19(4):218–223 (in Russ.).
31. Korelina V.E. Study of the correction of lipid peroxidation by antioxidants in experimental glaucoma (experimental study): thesis. 1999 (in Russ.).
32. Alekseev V.N., Korelina V.E., Shasha Ch. Neuroprotection with the new antioxidant Rexod in experimental glaucoma. Clinical ophthalmology. 2008 (3):82–83 (in Russ.).
33. Alekseev V.N., Sadkov V.I., Aksenova A.N. et al. Neuroprotection in POAG VI International conference “Glaucoma: theories, trends, technologies. HRT Club Russia 2008”. 2008:1–9 (in Russ.).
34. Salt T., Cordeiro M. Glutamate excitotoxicity in glaucoma. Eye Lond Engl. 2006;20(6):730–732. DOI: 10.1038/sj.eye.6701967.
35. Goyal A., Srivastava A., Sihota R., Kaur J. Evaluation of oxidative stress markers in aqueous humor of primary open angle glaucoma and primary angle 85 closure glaucoma patients. Curr Eye Res. 2014;39(8):823–829. DOI: 10.3109/02713683.2011.556299.
36. Kurysheva N.I., Markicheva N.A., Nagornova N.D. et al. Metabolic concept of the pathogenesis of glaucomatous optic neuropathy. Scientific-practical. conf. “Modern technologies for the treatment of glaucoma” 2003:87–95 (in Russ.).
37. Bredt D.S., Hwang P.M., Snyder S.H. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature. 1990;347:768–770.
38. Yucel Y. The evidence for glaucoma as a neurodegenerative disease. International Glaucoma Review Supplement. 2006;8(3):27–29.
39. U.S. Census Bureau, Household Pulse Survey. 2020–2021.
40. Otori Y., Takahashi G., Urashima M., Kuwayama Y. Evaluating the Quality of Life of Glaucoma Patients Using the State-Trait Anxiety Inventory. Quality of Life Improvement Committee. J Glaucoma. 2017;26(11):1025–1029. DOI: 10.1097/IJG.0000000000000761.PMID:28858160.
41. Rezapour J., Nickels S., Schuster A.K. et al. Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study. BMC Ophthalmol. 2018;18(1):157. DOI: 10.1186/s12886-018-0831-1.
42. Lakosina N.D. Clinical psychology. M.: MEDpress-inform Publ; 2007 (in Russ.).
43. Lichko A.E., Ivanov I. Ya. Medical and psychological examination of somatic patients. Journal of Neurology and Psychiatry. S.S. Korsakov. 1980;4:1195–1198 (in Russ.).
44. Mendelevich V.D. Clinical and medical psychology. M.: MEDpress-inform Publ; 2008 (in Russ.).
45. Méndez-Ulrich J.L., Sanz A., Feliu-Soler A. et al. Could White Coat Ocular Hypertension Affect to the Accuracy of the Diagnosis of Glaucoma? Relationships Between Anxiety and Intraocular Pressure in a Simulated Clinical Setting. Appl Psychophysiol Biofeedback. 2018;43(1):49–56. DOI: 10.1007/s10484-017-9385-x.
46. Callard F., Perego E. How and why patients made Long Covid. Soc Sci Med. 2021;268:113426. DOI: 10.1016/j.socscimed.2020.113 426.
47. NICE: COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188]. (Electronic resource.) URL: https://www.nice.org.uk/ guidance/ng188 (access date: 18.12.2020).
48. Martijn A. Spruit, Anne E. Holland, Sally J. et al. COVID-19: Interim Guidance on Rehabilitation in the Hospital and Post-Hospital Phase from a European Respiratory Society and American Thoracic Society-coordinated International Task Force. Eur Respir J. 2020. DOI: 10.1183/13993003.02197-2020.
49. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome The Journal of the American College of Cardiology February 23, 2021.
50. Baranova N.A. The degree of nocturnal decrease in blood pressure in patients with glaucoma, as a factor affecting fluctuations in ophthalmotonus. Glaucoma news. 2015;1(33):89–90 (in Russ.).
51. Erichev V.P., Kozlova I.V., Makarova A.S. Jin D. Features of systemic hemodynamics in patients with primary open-angle glaucoma, compensated intraocular pressure and unstabilized course. National Journal of Glaucoma. 2013;3:20–23 (in Russ.).
52. Kanchenska K., Rich R., Traverso K.E. et al. Flammer’s Syndrome. National Journal of Glaucoma. 2016;15(4):3–11 (in Russ.).
53. Egorov E.A. National guide to glaucoma. M.: GEOTAR-Media; 2019 (in Russ.).
54. Kuroedov A.V., Yerichev V.P., Khodykina N.P. et al. On the correlation relationship between daily fluctuations in intraocular pressure and the morphometric structure of the optic nerve head. Ophthalmology. 2006;3(1):43–49 (in Russ.).
55. Gordon M.O., Beiser J.A., Brandt J.D. et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmology. 2002;120:714–720.
56. Impact of the COVID–19 pandemic on patients with glaucoma. Aeconomics. (Electronic resource.) URL: https://aeconomy.ru/news/other/vliyanie-pandemii-covid-19-na-pacientov-s-glaukomoj.html (access date: 10.03.21) (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать